First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

被引：12

作者：

Parikh, Ravi B. ^{[1
]}

Feld, Emily K. ^{[1
]}

Galsky, Matthew D. ^{[2
]}

Adamson, Blythe J. S. ^{[3
,4
]}

Cohen, Aaron B. ^{[3
,5
]}

Baxi, Shrujal S. ^{[3
]}

Ben Boursi, Shimon ^{[1
]}

Christodouleas, John P. ^{[6
]}

Vaughn, David J. ^{[1
]}

Meropol, Neal J. ^{[3
,7
]}

Mamtani, Ronac ^{[1
]}

机构：

[1] Univ Penn, Dept Med, Philadelphia, PA 19104 USA

[2] Icahn Sch Med, Tisch Canc Inst, New York, NY 10029 USA

[3] Flatiron Hlth, New York, NY 10013 USA

[4] Univ Washington, Policy & Econ CHOICE Inst, Comparat Hlth Outcomes, Seattle, WA 98195 USA

[5] NYU, NYU Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA

[6] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA

[7] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 02期

基金：

美国国家卫生研究院;

关键词：

chemotherapy; European Medicines Agency; Food and Drug Administration; immunotherapy; real-world data; urothelial cancer; INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; UNFIT;

D O I：

10.2217/fon-2019-0578

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Standard first-line treatment of advanced urothelial cell carcinoma involves cisplatin-based chemotherapy, with carboplatin or immune checkpoint inhibitor therapy (ICI) reserved for cisplatin-ineligible individuals. Methods: Using a large de-identified electronic health record-derived database of patients with advanced urothelial cell carcinoma in the USA, we examined trends in utilization of first-line systemic therapies in cisplatin-eligible patients from 1 January 2015 to 31 March 2018. Results: Among 1181 cisplatin-eligible patients, the quarterly proportion who received first-line ICI increased from 1 to 42% (p(trend) <0.001), while the proportion who received cisplatin-based chemotherapy decreased from 53 to 33% (p(trend) = 0.018). Patients receiving ICI were older than those receiving cisplatin (median age: 75 vs 68). Conclusion: Our analysis suggests rising off-label ICI use in cisplatin-eligible individuals, potentially because of ICI's favorable toxicity profile.

引用

页码：4341 / 4345

页数：5

共 11 条

[1] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].

Balar, Arjun V. ;

Castellano, Daniel ;

O'Donnell, Peter H. ;

Grivas, Petros ;

Vuky, Jacqueline ;

Powles, Thomas ;

Plimack, Elizabeth R. ;

Hahn, Noah M. ;

de Wit, Ronald ;

Pang, Lei ;

Savage, Mary J. ;

Perini, Rodolfo F. ;

Keefe, Stephen M. ;

Bajorin, Dean ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2017, 18 (11) :1483-1492

[2] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[3] A WILCOXON-TYPE TEST FOR TREND [J].

CUZICK, J .

STATISTICS IN MEDICINE, 1985, 4 (01) :87-90

[4]

European-Medicines-Agency, 2018, Press release

[5]

Flaig TW, 2018, NCCN CLIN PRACTICE G

[6]

Flatiron Health Database, 2018, FLAT HLTH DAT

[7] Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy [J].

Galsky, Matthew D. ;

Hahn, Noah M. ;

Rosenberg, Jonathan ;

Sonpavde, Guru ;

Hutson, Thomas ;

Oh, William K. ;

Dreicer, Robert ;

Vogelzang, Nicholas ;

Sternberg, Cora N. ;

Bajorin, Dean F. ;

Bellmunt, Joaquim .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2432-2438

[8] A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy [J].

Galsky, Matthew D. ;

Hahn, Noah M. ;

Rosenberg, Jonathan ;

Sonpavde, Guru ;

Hutson, Thomas ;

Oh, William K. ;

Dreicer, Robert ;

Vogelzang, Nicholas ;

Sternberg, Cora ;

Bajorin, Dean F. ;

Bellmunt, Joaquim .

LANCET ONCOLOGY, 2011, 12 (03) :211-214

[9] Off-label use of anticancer drugs [J].

Leveque, Dominique .

LANCET ONCOLOGY, 2008, 9 (11) :1102-1107

[10] A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation [J].

Levey, AS ;

Bosch, JP ;

Lewis, JB ;

Greene, T ;

Rogers, N ;

Roth, D .

ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :461-+

← 1 2 →